Given that coexistence of osteoporosis and sarcopenia is prevalent in the elderly population, the potential benefit of anti-RANKL treatment in possibly mitigating skeletal muscle atrophy while enhancing bone mechanical properties should be further investigated. The gene discussed is TNFSF11; the disease is sarcopenia.